QUARTER-END POSITION / VERSION 2

ACADIA PHARMACEUTICALS INC.

ACADIA PHARMACEUTICALS INC

published

Reporting manager: Bridgewater Associates, LP
Relationship: Associated institution
Record date: 30 Jun 2026
Date meaning: Original Form 13F report period
Quantity: 50,265 shares
Reported value / amount: $1,271,705
Weight and denominator: 0.01% · Calculated: issuer/class value divided by the complete original reported table; not personal wealth
Quarter-end reported price: Not disclosed · Price at record date, not purchase cost
Derived value per reported unit: $25.30001 · Reported value ÷ reported quantity (shares); not an observed market price
Source-reported activity: Not disclosed
Coverage: Complete original information table grouped by CUSIP and security class
Reviewed by: DeepSeek AI
Published: 20 Oct 2026

Original regulatory disclosure; 1 original filing line(s) grouped within this issuer/class. Absence from a disclosed table is not private account verification.

Reporting-entity association: Inspect the identity evidence

Original filing attribution · 1 line(s)

Reporting manager: Bridgewater Associates, LP. 13F HOLDINGS REPORT. These are reported investment-discretion relationships, not proof of beneficial ownership or a personal account. Each original line is counted once, including lines naming multiple managers.

ORIGINAL LINE	REPORTED QUANTITY / VALUE	OTHER MANAGER / DISCRETION	VOTING AUTHORITY
11	50,265 shares$1,271,705	No included manager referencedOriginal field: Not stated · Discretion: SOLE	Sole 50,265Shared 0 · None 0

View quotation / manual copy ↗

Editorial note: Independent AI source review 2026-10-21T00:13:56.744+08:00; batch bf97274c9f25c6001e21f1552a856c3d9d7b0c82f4fbf0763b180426cd8ed183. Original filing quantities, metadata and row attribution checked. Holdings facts only; corporate-action and period comparisons are not reviewed. This is AI review, not a human or private-account audit.

Sources.

Original disclosure

Bridgewater Associates, LP — 13F-HR — 2026-06-30

U.S. SEC EDGAR · Published 14 Aug 2026 · Collected 20 Oct 2026

Details ↗Open in the source library ↗

Version history.

Version 2published · 20 Oct 2026

Independent AI source review 2026-10-21T00:13:56.744+08:00; batch bf97274c9f25c6001e21f1552a856c3d9d7b0c82f4fbf0763b180426cd8ed183. Original filing quantities, metadata and row attribution checked. Holdings facts only; corporate-action and period comparisons are not reviewed. This is AI review, not a human or private-account audit.

Corrections preserve the original record.Suggest a correction ↗

BUILT WITH YOUR INPUT

Your comments help
HoldingsAtlas grow.

Tell us what is useful, what is missing and what we could do better. Your feedback matters.

Visit the feedback page ↗

Copy a dated citation.

English factual summary

Bridgewater Associates, LP reported 50,265 shares of ACADIA PHARMACEUTICALS INC as of 2026-06-30. Reported value: $1,271,705. Weight: 0.01% of Calculated: issuer/class value divided by the complete original reported table; not personal wealth. This is a dated quarter-end position, not a live position, purchase cost or the associated person’s personal account. Filing type: 13F HOLDINGS REPORT. Manager references describe reported investment discretion, not beneficial ownership.
Source: U.S. SEC EDGAR — https://www.sec.gov/Archives/edgar/data/1350694/000135069426000003/infotable.xml | Published: 2026-08-14 | Collected: 2026-10-20T15:44:23.011Z
Record: https://holdingsatlas.com/records/14cdcfde-7105-4226-a5b6-e3f55a4284e8/

If copying is unavailable, select the text above and copy it manually.